Shares of US biotech Moderna (Nasdaq: MRNA) jumped to nearly $108 on Wednesday after the firm revealed encouraging data for its cancer vaccine, mRNA-4157.
The jab is being offered as part of a combination therapy, together with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab), the leading checkpoint blocker on the market.
The company outlined the results through a poster presentation at the annual meeting of the American Association for Cancer Research (AACR), in San Diego, USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze